Cullinan Therapeutics (CGEM) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Kura Oncology (KURA) over the past year, gaining 139.7% versus a gain of 4.4%. Over five years, CGEM leads with a -38.2% price change compared with -41.6% for KURA. Cullinan Therapeutics is the larger company by market cap ($950.4 million vs $929.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | KURA |
|---|---|---|
| Share price | $15.47 | $10.45 |
| Market cap | $950.45M | $929.19M |
| 1-day change | +0.03% | -0.71% |
| YTD return | +49.37% | +1.25% |
| 1-year return | +139.69% | +4.37% |
| 5-year return | -38.16% | -41.62% |
| EPS (TTM) | $-3.11 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $13.90 |
| 52-week low | $6.73 | $7.36 |
| Distance from 52-week high | -33.31% | -24.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.29% | +204.93% |
| Average volume | 881.85K | 1.77M |
| Shares outstanding | 61.46M | 88.96M |
| Employees | 109 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed KURA by 135.3 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
CGEM vs KURA FAQ
Which is bigger, Cullinan Therapeutics or Kura Oncology?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $950.45M compared with $929.19M for Kura Oncology (KURA).
Which stock has performed better over the past year, CGEM or KURA?
CGEM returned +139.69% over the past 12 months, compared with +4.37% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Kura Oncology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cullinan Therapeutics and Biotechnology: Pharmaceutical Preparations for Kura Oncology.